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The appetite test is used to risk-stratify for children with severe acute malnutrition (SAM) in in-patient or out-29 
patient care. The test is recommended in guidelines despite lack of evidence. We evaluated its ability to identify 30 
children at risk of a poor treatment outcome. 31 
 32 
Methods 33 
We conducted an observational study of children diagnosed with SAM at three health facilities in Ethiopia. 34 
The appetite test was done independently of the routine staff, and the result did not affect decisions about 35 
hospitalisation and clinical care. Data was analysed using mixed linear and logistic regression models. 36 
 37 
Results 38 
The appetite was tested in 298 (89%) of the 334 children enrolled; 56 (19%) passed. Children failing the 39 
appetite test had a 6·6% higher weight gain per day (95% CI 2·6, 10·8) adjusted for type of treatment, oedema, 40 
duration of follow up, and age than children passing the test. We found medical complications in 179 (54%) 41 
children. Medical complications were associated with blood markers of metabolic disturbance. Children with 42 
medical complications tended to have lower weight gain than those without complications (3·5%, 95%CI -43 




Our findings question the use of the appetite test to identify children who need in-patient care. An assessment 48 
of medical complications alone could be a useful risk indicator but needs to be evaluated in other settings. 49 
 50 
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Severe acute malnutrition (SAM) is a condition with high mortality mostly affecting children in low- and 55 
middle-income countries (1). It is recommended that children with SAM and either poor appetite or medical 56 
complications should be hospitalized, while children with good appetite and no medical complications can be 57 
treated as out-patients with ready-to-use therapeutic foods (RUTF) (2, 3). Originally, appetite was assessed 58 
roughly to help decide if a child could be treated with RUTF (4). Later appetite assessment was standardized 59 
and included in the guidelines for treating children with SAM to identify children that could be treated as out-60 
patients (5-7). A failed “appetite test” is now used as a proxy for sepsis or major metabolic abnormality, defined 61 
as "liver dysfunction, electrolyte imbalance, and cell membrane damage or damaged biochemical pathways" 62 
(5) and therefore risk of poorer treatment response and need for hospitalization.  63 
 64 
Limited information is available on appetite in malnourished children and the rationale behind the test is a 65 
proposed link between infection and food intake, and the fact that severe infections cause anorexia (8-10). The 66 
authoritative emphasis placed on the appetite test in international and national guidelines is not based on 67 
scientific evidence (3, 5). The World Health Organization (WHO) acknowledges this and recommends that 68 
validating the appetite test should be a research priority (3). A recent review of methods for appetite assessment 69 
did not find any studies that have clinically validated the appetite test (11). The test is complex and time-70 
consuming and a cut-off for appetite to reliably identify children in need of hospitalization has not been 71 
established. 72 
 73 
We here present the first clinical study to evaluate the ability of the appetite test to identify children with SAM 74 
in need of hospitalization. Our objective was to evaluate the usefulness of the test for identifying SAM children 75 
with sepsis or major metabolic abnormality, and to determine if the appetite test can identify children with 76 
poorer treatment outcomes and need for hospital admission. The secondary objective was to evaluate 77 
alternative versions of the appetite test and other prognostic markers for complications including a simple 78 






Study design and participants 82 
The study was conducted in three health facilities in Ethiopia. Jimma University Specialized Teaching Hospital 83 
(JUSTH) treated children that were referred from lower level health facilities or came directly to the hospital. 84 
Serbo Health Centre (SHC) covered a neighbouring rural area and received patients directly or referred from 85 
community health workers. The Missionaries of Charity Clinic (MiCC) in Jimma town received patients 86 
directly from the town and surrounding rural area. In JUSTH and MiCC all children with SAM were admitted, 87 
regardless of severity of the disease. Patients Children with SAM were enrolled at JUSTH from June 2016 and 88 
we expanded to SHC in February 2017 and to MiCC in June 2017, because of a lower caseload than expected. 89 
We reached the target sample size of 330 children in May 2018. The enrolled children were treated according 90 
to the national protocol (12), based on recommendations of the WHO (3), using F-75 (Aspen nutritionals, 91 
Pharmacare, South Africa), F-100 (Nutriset, Malaunay, Frace), or RUTF (Plumpy’Nut™, Nutriset, Hilina 92 
Enriched Foods, Addis Ababa, Ethiopia) and empiric antibiotic treatment with amoxicillin (50-100 mg/kg/d) 93 
with the addition of gentamicin (5 mg/kg/d) for in-patients. Most children were treated for a few days with F-94 
75 and F-100 before changing to RUTF, irrespective of their signs and symptoms. It was not routine clinical 95 
practice to use the appetite test in the study sites; in JUTSH and MiCC all children with SAM were admitted 96 
for in-patient care, irrespective of severity, and in SHC the decision to admit was based on the presence or 97 
absence of medical complications.  98 
 99 
The study was a prospective observational study, to evaluate if a standardised appetite test, conducted at the 100 
time of enrolment, could be used to grade disease severity and predict clinical outcome. The children were 101 
initially investigated by the clinical staff, who managed the patients independently of the research staff. Before 102 
any treatment was started, the research staff informed the parents about the study and asked for written consent 103 
to let their children participate. The research staff then performed the appetite test, drew a venous blood sample 104 
and collected demographic and clinical data using standardized case report forms. Disease severity at 105 
enrolment was assessed clinically and based on blood tests. Clinical outcome was monitored at weekly follow-106 




died, were transferred to a higher-level health facility or were undergoing treatment or still had SAM with no 108 
further follow-up data available after 4 weeks of treatment. 109 
 110 
We enrolled all children from 6 months to 15 years with SAM. Inclusion criteria were one or more of the 111 
following; weight-for-height<70% of the median of the National Center for Health Statistics (NCHS) reference 112 
curve, mid-upper arm circumference (MUAC) <115mm, or bilateral oedema. The appetite test was not 113 
performed if a child had overt signs of critical illness such as unconsciousness, convulsions, need of oxygen, 114 
active bleeding, or required admission to the intensive care unit for other reasons as decided by the clinical 115 
staff. 116 
  117 
Appetite test 118 
We used the weight-based test, where the children pass the test if they eat a pre-specified amount of RUTF 119 
relative to their weight (5), as the primary predictor (Table 1). We also evaluated other definitions of reduced 120 
appetite including the weight-independent test where the children pass the test if they eat at least one third of 121 
the RUTF sachet (6, 7) and a “new appetite test” that was passed if more than one-tenth of the sachet had been 122 
eaten. 123 
 124 
Table 1: Intake cut-offs for weight-based appetite test 
Child weight:  Test was passed if the child ate this amount, or more:  
less than 4 kg  1/8 of the sachet 
more or equal than 4 kg, but less than 7 kg  1/4 of the sachet 
more or equal than 7 kg, but less than 10 kg  1/3 of the sachet 
more or equal than 10 kg, but less than 15 kg  1/2 of the sachet 
more or equal than 15 kg, but less than 30 kg  3/4 of the sachet 
more or equal than 30 kg  1/1 of the sachet 
 125 
The RUTF sachet was weighed to the nearest gram (Sartorius TE412 in JUSTH and EatSmart ESKS in MiCC 126 




the test. After 30 minutes, the test was stopped, and the sachet was weighed again. The research nurse did not 128 
determine whether the test was passed or not, but only recorded the amount eaten. In addition to the formal 129 
appetite test, the research nurse subjectively categorized the child’s appetite as either “refused” to eat, “poor”, 130 
or “good”. The results were not made available to the clinical staff.  131 
 132 
Clinical parameters 133 
We weighed the children daily during admission and at all follow up visits (Tanita BD-815 MA Infant 134 
weighing scale, Japan and Seca weighing scale, Germany). At admission we also measured length or height 135 
and MUAC (Seca height and length boards, Germany and MUAC tapes, UNICEF, Denmark). We tested for 136 
medical complications at admission, defined as one or more of the following; axillary temperature <35°C or 137 
>39°C, grade three oedema (pitting oedema of entire body), repeated (≥3 times) vomiting during the appetite 138 
test, admission to intensive care, history of convulsions, palmar paleness, fast breathing, or chest in-drawing 139 
(13, 14).  140 
 141 
Laboratory methods 142 
One EDTA plasma tube (Vacuette, Becton Dickinson (BD), Austria) and, if the child was not admitted to 143 
intensive care, one Serum Sep Clot tube (Vacuette, BD, Austria) were obtained. Furthermore, blood cultures 144 
were performed using aerobic and anaerobic blood culture vials (BACTEC Peds Plus and BACTEC Lytic/10 145 
Anaerobic, BD, USA) as previously described (15).  146 
 147 
Blood cultures were incubated in an automatic blood culture system (BACTEC FX40, BD, USA) and positive 148 
cultures were subcultured on agar plates. The results of the initial identification and susceptibility testing in 149 
the local microbiology laboratory were reported to the clinical staff without delay. Isolates were frozen at -150 
80°C, shipped to Denmark, and identified using Matrix-Assisted Laser Desorption Ionization–time of flight 151 






The complete blood count was analysed on an automated haematology analyser (KX-21 N, Sysmex 155 
Corporation, Bellport, USA) and samples were tested for malaria using rapid diagnostic tests, (First Response 156 
Malaria Ag (pLDH/HRP2), Premier Medical Corporation, Daman, India). After centrifugation of the primary 157 
tubes, plasma and serum were aliquoted in cryovials and frozen at -80°C. The samples were sent to the 158 
Denmark, and analysed at the Department of Clinical Biochemistry, Rigshospitalet, for aminotransaminases 159 
(ALT), albumin, bilirubin, creatinine, calcium (Ca), C-reactive protein (CRP), magnesium (Mg), phosphate 160 
(PO4), sodium (Na), and potassium (K) (Cobas, Roche Diagnostics, USA). The serum samples were screened 161 
for HIV at the Department of Clinical Immunology, Rigshospitalet using Vitros anti-HIV1+2 Enzyme 162 
Immunoassay (Ortho Clinical Diagnostics, Pencoed Bridgend, UK), and initial screen reactive samples were 163 
submitted to confirmatory testing (INNO-LIA HIV I/II Score, Fujirebio Europe, Gent, Belgium). Datasets and 164 
samples were de-identified by assigning unique study id numbers, before shipping samples to Denmark. 165 
 166 
Statistical analysis 167 
We used bacteraemia as the outcome in our sample size calculation, since we expected this would be the rarest 168 
outcome. We assumed that the bacteraemia proportion would be at least 15% in cases failing the appetite test 169 
and 5% in cases passing the test(16) and that we would not get appetite test results from 20 cases. With a 95% 170 
CI and 80% power we calculated a minimum sample size of 330 children. Age was categorized as 6-11, 12-171 
23, 24-59, and >59 months in the statistical analysis. We entered and validated data with EpiData 3·1 (EpiData, 172 
Odense, Denmark) and used SAS Enterprise Guide, Version 7·11 of the SAS System for Windows (SAS 173 
Institute Inc., Cary, NC, USA) for data analysis. A p value lower than 0·05 was considered significant and 174 
95% CIs were used throughout the analyses. Weight-for-height/length z-score (WHZ) was based on WHO 175 
standards (17). We used Chi-square test to compare differences in proportions and a general linear model for 176 
continuous variables. We used a mixed linear model for continuous outcomes and a mixed logistic regression 177 
model for binary outcomes, both with random effects for site to adjust for any potential differences between 178 
the sites. Weight was log transformed to ensure normal distribution. Weight gain was calculated at each 179 
measurement as relative weight gain per day (g/kg/day) compared with the first oedema-free weight. We used 180 




test) on weight gain (presented as percent difference between the two groups), adjusted for potential 182 
confounders (e.g. oedema and age), and added random effects for site and a Gaussian covariance structure for 183 
repeated measurements.  184 
 185 
Results  186 
Of 343 children screened, 334 (97%) had SAM and were enrolled, 228 (68%) at JUSTH, 78 (24%) at MiCC, 187 
and 28 (8%) at SHC (Figure 1). Of the 334 enrolled children, 298 (89%) had their appetite tested. One child 188 
had blood samples taken but died before admission data was collected. Data on mortality was available for 189 
283 (85%) of the study participants of whom 17 (6%) died and another 57 (20%) had likely treatment failure. 190 
We had sufficient data on weight and treatments from 95 (28%) children for evaluating the effect of the appetite 191 
test on weight gain. We had sufficient data from 112 children for evaluating the effect of medical complications 192 
























Figure 1: Flow diagram 
  
343 children screened 
Appetite test not done: 36 
- Admitted to intensive care: 32 
- Unable to swallow: 2 
- Enrolled after treatment was initiated: 1 
- Enrolled when RUTF was unavailable: 1 
No follow up information available: 15 
 
 
283 children had their appetite tested and follow up 
data available 
Did not have SAM: 9 
334 children enrolled in the study 
298 children had their appetite tested  




95 children had their appetite tested and sufficient 




Table 2: Baseline characteristics of enrolled children with severe acute malnutrition 
 na Value 
Female sex, % (n) 333 48% (160) 
Age, monthsb 333 33·0 (14·0; 60·0)  
       > 59, % (n) 333 27% (90)  
Mid-upper arm circumferencec  332 117 (19) 
       among children without oedema  118 106 (16) 
Weight-for-length/height z-score (6-59 months)b,d 261 -2·7 (-3·8, -1·2) 
       among children without oedema 88 -3·7 (-4·8, -3·1) 
Length/height for age z-score (6-59 months)b,d 262 -3·3 (-4·4, -2·2) 
BMI for age (5-14 years)d 29 -4·0 (1·9) 3 
Bilateral oedema 333 63% (215) 
Medical complications 333 54% (179) 
Referred from another health institution 293 54% (159) 
Treatment for malnutrition during the last week 282 9% (24)  
Treatment with antibiotics during the last week 310 16% (50)  
a Number of children for whom data was available 
b Median (25th; 75th percentiles) 
c Mean (standard deviation) 
d WHO z-scores 
  
 196 
Appetite test  197 
Of the 298 children (89%) who had their appetite tested, 56 (19%) passed the weight-based test. Of the 36 198 
cases that did not have their appetite tested, 34 (94%) had a clinical condition that precluded testing. Among 199 
these 34 children, 2 (6%) were unable to swallow due to developmental disorders and 32 (94%) were admitted 200 
to intensive care due to critical illness (Figure 1). The appetite test result was not correlated with age, admission 201 
weight, first oedema-free weight, bilateral oedema, WHZ, or MUAC (Table 3). Results were similar in the 202 
subgroup of children with sufficient data to be included in the weight gain model, including the result of the 203 
appetite test (19% passed both overall and in the subgroup). Children failing the appetite test received 204 
gentamicin more often than children that passed the test (p=0·04). The adjusted weight gain per day was 6·6% 205 
higher in children failing compared with children passing the appetite test (6·6, 95% CI 2·6, 10·8, p=0·002) 206 




oedema, duration of follow up, and age. Adjustment for number of days on F-75, F-100, and RUTF did not 208 
affect the estimate, i.e. we still found a higher weight gain in those failing the test (p=0·004). Lastly, only 209 
adjusting for oedema, duration of follow up, and age had limited effect on the result (5·5, 0·06, 9·9, p=0.03). 210 
Replacing the first oedema-free-weight with the lowest weight observed after oedema had receded in the model 211 
gave similar results.   212 
 213 
Table 3: Comparison of children passing or failing the appetite testa 
 Passed appetite test 
(n=56) 
Failed appetite test 
(n=242) 
p 
Age, monthsb 36 (14, 66) 30 (14, 60) 0·64 
Admission weight, kgb 8·9 (6·5, 13·0) 8·6 (6·7, 11·5) 0·89 
First oedema-free weight, kgb 8·3 (5·7, 13·3) 8·3 (6·0, 11·1) 0·73 
Bilateral oedema, n (%)  31 (55) 165 (68) 0·07 
WHZb -2·6 (-3·5, -1·6) -2·5 (-3·7, -1·0) 0·23 
MUAC, mm, mean (sd) 115 (20) 119 (18) 0·19 
Diarrhoea, n (%)   25 (45%) 130 (54%) 0·25 
a Tested in a mixed model linear regression with random effects for site and variables log-transformed, except WHZ and MUAC. Data available 
for 298 children. 
b Median (25th; 75th percentiles) 
 214 
Table 4: Difference in weight gain per day between proposed risk indicators 
Test Variable Criteria Percent difference in 
weight gain per day  
(95 % CI) 
p 
Standard appetite test Failed - passed Differentiated by weight, see table 1 6·6 (2·6, 10·8) 0.002 
Weight independent 
appetite test 
Failed - passed The test was passed if a child ate at least 1/3 of 
the sachet regardless of the child’s weight 
5·7 (-20·3, 40·2) 0·7 
New appetite test Failed - passed The test was passed if a child ate at least 1/10 of 
the sachet regardless of the child’s weight 
5·5 (1·5, 9·7) 0·007 
Nurses’ evaluation of 
child’s appetite 




Medical complications With - without Defined as presence of at least one of the 
following; temperature <35°C or >39°C, grade 3 
oedema, vomiting everything during appetite test, 
admission to intensive care, history of 
convulsions, palmar paleness, fast breathing, or 
chest indrawing 
-3·5 (-7·0, 0·25) 0.07 
Tested in a mixed model linear regression with random effects for site and adjusted for F75, F100, RUTF, gentamicin, oedema, age, and duration 
of follow up. Weight gain was calculated by subtracting first oedema free weight from the follow up weights divided by first oedema free weight 
and measured as gain per day (g/kg/day). Difference between the two groups is presented as percent difference. Weight gain per day was the 
interaction term between the appetite test result and the effect on weight gain of the number of days of treatment after the first oedema-free 
weight  
 215 
Overall case fatality was 6·0% (n=17), but 31% of the children that died had not had their appetite tested, 216 
mostly because the child was not in a condition to collaborate. For children completing the test there was a 217 
case fatality of 4·9% among children failing the appetite test and 4·3% among children passing it (OR 1·31, 218 
95% CI 0·05, 33·29, p=0·87, adjusted for type of treatment given, oedema and age). Treatment failure, 219 
caregiver assessment of their child’s illness after three months, and bacteraemia were not correlated with the 220 
result of the appetite test. Children that failed the appetite test had lower serum calcium than children that 221 
passed (p=0·009), whereas all other measured markers of metabolic disturbances did not differ between the 222 
two groups (Table 5). 223 
 224 
Table 5: Correlation of laboratory tests with the appetite test resulta 
 n (passed/failed) Passed appetite test Failed appetite test p 
Infection-related 
Bacteraemia, n (%) 231 (39/192) 0 (0) 8 (4) 0·19 
CRP, mg/Lb  242 (45/197) 4 (1, 14) 12 (3, 37) 0·09 
Platelets, 103/µlb 263 (47/216) 356 (172, 497) 304 (190, 452) 0·48 
Haematology 
Hb, g/dlc  263 (47/216) 10·0 (2·4) 10·1 (2·2) 0·76 
WBC, 103/µlb 263 (47/216) 9·0 (6·8, 12·9) 10·2 (7·9, 13·7) 0·17 
Biochemistry 




Albumin, g/Lb 242 (45/197) 24 (17, 30) 17 (11, 26) 0·056 
Bilirubin, µmol/Lc 242 (45/197) 2 (4) 3 (5) 0·29 
Creatinine, µmol/Lc 242 (45/197) 25 (9) 26 (9) 0·42 
Calcium, mmol/Lc 222 (41/181) 2·08 (0·28) 1·94 (0·27) 0·009 
Potassium, mmol/Lc 196 (35/161) 4·3 (0·8) 4·1 (1·1) 0·47 
Magnesium,mmol/Lc 222 (41/181) 0·86 (0·11) 0·82 (0·14) 0·33 
Sodium, mmol/Lc  222 (41/181) 137 (3) 136 (6) 0·17 
Phosphate, mmol/Lc 237 (45/192) 1·33 (0·35) 1·22 (0·32) 0·09 
a Tested in a mixed model linear regression with random effects for site  
b Median (25th; 75th percentiles), variables log-transformed 
c Mean (standard deviation) 
 
 225 
Medical complications 226 
One or more medical complications were present in 179 (54%) of the patients. We found that children without 227 
medical complications had a higher weight gain, adjusted for type of treatment given, oedema, duration of 228 
follow up, and age, than children with complications, but the difference was not statistically significant (3·5% 229 
difference, 95% CI -0·25, 7·0, p=0.07). Medical complications at admission were not correlated with mortality. 230 
The first oedema-free weight, age, prevalence of bilateral oedema, MUAC, and WHZ did not differ between 231 
the two groups with and without complications, and this was also the case among the children for which we 232 
had sufficient data for the weight gain model. Treatment failure and the caregivers’ assessment of their child’s 233 
illness after three months were not correlated with medical complications. However, medical complications 234 
were correlated with several of the laboratory investigations (Table 6). 235 
 236 
Table 6: Correlation of laboratory tests with medical complicationsa,b 
 n  
(without/with medical 
complications) 
No medical complications Medical complications p 
Infection-related 
Bacteraemia, n (%) 258 (119/139) 3 (2·5) 8 (5·8) 0·21 




Platelets, 103/µld 296 (134/162) 314 (195, 460) 296 (173, 455) 0·25 
Haematology 
Hb, g/dld  296 (134/162) 10·5 (2·2) 9·6 (2·4) 0·001 
WBC, 103/µlc 296 (134/162) 9·9 (7·8, 13·7) 10·5 (7·8, 13·6) 0·96 
Biochemistry 
ALAT, U/Lc  256 (117/139) 22 (13, 34) 29 (18, 49) 0·007 
Albumin, g/Lc 268 (123/145) 24 (15, 31) 14 (9, 21) <0·0001 
Bilirubin, µmol/Ld 268 (123/145) 2 (3) 4 (7) 0·002 
Creatinine, µmol/Ld 268 (123/145) 26 (10) 26 (10) 0·98 
Calcium, mmol/Ld 223 (117/106) 2·05 (0·29) 1·87 (0·25) <0·0001 
Potassium, mmol/Ld 196 (104/92) 4·1 (1·1) 4·1 (1·0) 0·92 
Magnesium,mmol/Ld 223 (117/106) 0·85 (0·13) 0·80 (0·14) 0·01 
Sodium, mmol/Ld  223 (117/106) 137 (4) 136 (6) 0·32 
Phosphate, mmol/Ld 262 (121/141) 1·31 (0·33) 1·18 (0·31) 0·002 
a Defined as one of the following; temperature < 35°C or >39°C, grade 3 oedema, vomiting everything during appetite test, admission to intensive 
care, history of convulsions, palmar paleness, fast breathing, or chest indrawing 
b Tested in a mixed model linear regression with random effects for site  
c Median (25th; 75th percentiles), variables log-transformed 
d Mean (standard deviation) 
 
 237 
Alternative methods of assessing the appetite 238 
We also evaluated alternative appetite tests and for the “new appetite test” we got similar results as for the 239 
weight-based appetite test, with a higher weight gain among those failing compared with those passing the 240 
tests (Table 4). We adjusted for type of treatment given, oedema, duration of follow up, and age. We did not 241 
find any association between weight gain and the results of the weight-independent test. Passing the weight-242 
independent appetite test was correlated with higher serum phosphate (p=0·05). We finally evaluated the 243 
discriminatory ability of appetite as assessed subjectively by the study nurses. There was no difference between 244 
the group the nurses categorized as “refused” to eat and a combined group of those with “poor” or “good” 245 
appetite, but children that either “refused” or had a “poor” appetite had a higher weight gain than children with 246 






Discussion  250 
The main finding of our study is the somewhat counterintuitive observation that children that passed the 251 
appetite test had a slower weight gain during follow up than children that failed the test. Furthermore, a failed 252 
appetite test was not associated with clinical severity or metabolic abnormalities. Alternative methods for 253 
evaluating the appetite, including tests recommended by international organizations (3, 7), gave similar results. 254 
The appetite test is currently recommended in national and international guidelines and in nutrition programs 255 
in most parts of sub-Saharan Africa and south Asia to determine whether children with SAM need 256 
hospitalization. The underlying assumption behind the use of the appetite test is that children with poor appetite 257 
will be more ill and gain weight at a slower rate if treated at home, and that they should therefore be treated as 258 
in-patients. To our knowledge, this is the first study to assess the clinical and predictive utility of the appetite 259 
test. We interpret our findings as evidence against its continued use and its continued inclusion in treatment 260 
guidelines. 261 
 262 
Although we did not formally blind the clinical staff, the study design effectively prevented that results of the 263 
appetite test could influence treatment decision. Furthermore, adjustment for duration and type of treatment 264 
did not alter the significance of our results. We stopped the appetite test after 30 minutes, even though 265 
continuing up to 60 minutes has been suggested (5), but we found it unfeasible to recommend an examination 266 
that would be even more time-consuming for busy low-level health workers.  267 
 268 
A limitation in our study, especially for the weight gain analysis, is the low number of children for which we 269 
had complete data. While we had follow-up information from 85% of the children, we only had data on both 270 
treatment and follow-up weight from 28%. We cannot rule out selection bias but the proportions and 271 
characteristics of children that failed and passed the appetite test did not change significantly after removing 272 
cases with incomplete follow-up data from the analysis. It is therefore unlikely that the strength and 273 





Comparing weight gain measured as gram per kg body weight will be unreliable if one of the groups being 276 
compared had heavier children on average, since the relative weight gain is smaller in children with a higher 277 
initial weight. However, we did not find any difference in first oedema-free weight between children failing 278 
and passing the test. 279 
 280 
In a large-scale nutrition program in which children were given a RUTF sachet while the caregiver was 281 
interviewed, not eating any of the content during a 10-minute period was correlated with mortality (18). We 282 
could not confirm this association, as there was no difference between the groups of children whose appetite 283 
had been subjectively classified by the nurse as “refused”, and children who were assessed as having “poor” 284 
or “good” appetite. A recent study from a referral hospital with a high HIV-prevalence suggested an association 285 
between lack of appetite and mortality, but only in the univariate analysis, and the investigators did not specify 286 
how they tested the appetite(19).  287 
 288 
The appetite test was not correlated with bacteraemia; however, our study may have had insufficient power as 289 
the prevalence of bacteraemia was lower than expected. The low positivity rate could be due to prior treatment 290 
with antibiotics and small sampling volumes for the blood cultures. We did a post hoc power calculation 291 
showing that we would be able to detect a difference in prevalence between 0·5% and 9% based on the 244 292 
cases that were included in the analysis. A low prevalence of bacteraemia was also reported in a recent 293 
multicentre study(20). The low prevalence of bacteraemia as opposed to the high positive rate of the appetite 294 
test (81%) would in any case render the appetite test very unspecific as a proxy marker for bacteraemia.  295 
 296 
Hypophosphatemia was more common in those failing the weight independent appetite test, but it has been 297 
argued that phosphate levels are a more relevant predictor for outcome when measured after initiation of 298 
treatment (21). Although the appetite test was correlated with reduced calcium levels this could be confounded 299 
by the fact that we did not test the appetite in children with convulsions or lethargy. We also did not find any 300 





As an alternative to the appetite test the Integrated Management of Childhood Illnesses (IMCI) guidelines(14) 303 
recommend using a list of medical complications as part of an algorithm to identify children with SAM in need 304 
of hospitalization. To our knowledge, this IMCI algorithm has never been evaluated, although studies have 305 
assessed the prognostic value of some of the clinical signs and symptoms included in it (21). This set of medical 306 
complications tended to indicate a lower weight gain during follow-up and to be associated with abnormal 307 
biochemistry results at admission. 308 
 309 
Conclusion 310 
In conclusion, our findings question the continued use of the appetite test to identify children with SAM for 311 
in-patient treatment. A best-case interpretation of our findings is that the appetite test is unreliable; a stricter 312 
interpretation is that the appetite test is directly misleading. Our findings should ideally be confirmed in other 313 
settings, particularly in community programs and sites from Asia. Further work will be needed to develop new 314 
clinical decision tools. Although not pre-defined as primary outcomes in this study, our findings indicate that 315 
a combination of signs and symptoms – broadly defined as “medical complications” – could be further 316 
evaluated as markers to identify children at risk of poorer treatment response.  317 
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